Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Head & Neck 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Ovarian Neoplasms 1Glioma 1

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Platinum Compounds × Genitourinary × Clear all
NCT04851834 2022-12-20

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Xennials Therapeutics Australia Pty Ltd

Phase 1/2 Terminated
12 enrolled
CNSGenitourinaryGynecologic

Urinary Bladder Neoplasms, Glioma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡